Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.
Economic assessment of eltrombopag in the treatment of thrombocytopenia / Romano, F.; Ruggeri, M.; Coretti, S.; Giannini, E. G.; Sacchini, D.; Annichiarico, B. E.; Marchetti, M.; Rodeghiero, F.; Lidonnici, D.. - In: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. - ISSN 1473-7167. - 15:4(2015), pp. 713-720. [10.1586/14737167.2015.1028373]
Economic assessment of eltrombopag in the treatment of thrombocytopenia
Coretti S.;Rodeghiero F.;
2015
Abstract
Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
